1. Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.
- Author
-
Van Sebille YZ, Stansborough R, Wardill HR, Bateman E, Gibson RJ, and Keefe DM
- Subjects
- Anti-Inflammatory Agents therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Drug Combinations, Fibroblast Growth Factor 7 therapeutic use, Gastrointestinal Tract drug effects, Humans, Hyaluronic Acid therapeutic use, Intestinal Mucosa drug effects, Mucositis chemically induced, Povidone therapeutic use, Practice Guidelines as Topic, Probiotics therapeutic use, Thrombospondins therapeutic use, Zinc Sulfate therapeutic use, Antineoplastic Agents adverse effects, Gastrointestinal Tract pathology, Intestinal Mucosa pathology, Mucositis therapy
- Abstract
Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
- Published
- 2015
- Full Text
- View/download PDF